# Repligen (RGEN)

Sector: Bioprocessing tools for life science

| Field | Value |
|---|---|
| Price | $163.81 |
| Market cap | $10B |
| Intrinsic value source | Analysts |
| Data as of | 2026-11-20 |
| Next earnings | 2027-02-23 (estimate) |

Analysts: Bullish

Picks: Research only

Discount category: Close to intrinsic value

## In short

The market weighs the steady bioprocessing growth of Repligen against new debt and the risks of the BioLife deal, and higher margins with growth in cell therapy through 2027 can lift its value.

## Themes and gap

- Themes: High debt (leverage)
- Gap type: Can close (closable)
- Why: The Q4 2026 report with 2027 guidance, expected in late February 2027, and the first year of BioLife show whether growth and margins rise as planned.

## About

Repligen Corporation (RGEN) is based in Waltham, Massachusetts. It makes bioprocessing products, such as filtration systems, chromatography products, proteins and analytics, that drug makers and contract manufacturers use to produce biologic drugs. On October 6, 2026, it bought BioLife Solutions, which makes cell processing tools for cell and gene therapy, for about $1.9 billion in cash and shares. Revenue was $209.3 million in Q3 2026, and organic growth was 12.5%. The common stock trades on the Nasdaq in US dollars. Repligen files 10-K and 10-Q reports.

## Thesis

The price of Repligen depends on whether bioprocessing demand keeps growing and whether BioLife adds the planned growth and margin. Revenue grew 12.5% organically in Q3 2026 and the company raised its 2026 revenue guidance to $844 million to $852 million, but it recorded a $41.2 million impairment of an intangible asset in Q3 2026, and it took on more debt for BioLife. For the price to rise, three things must be true. Orders for consumables and capital equipment must keep growing in 2027. BioLife must grow with the cell therapy market and deliver the more than $20 million of first-year synergies that the company expects. The adjusted EBITDA margin must rise above the 2026 level of about 21%. The Q4 2026 report with 2027 guidance, expected in late February 2027, is the next test. If biotech funding or drug maker orders slow, the high valuation multiples of the sector can fall.

## Checkpoints

- Feb 23, 2027 (estimate): Q4 2026 results and 2027 guidance. Status: Pending. Watch: 2026 revenue is in the guided range of $844 million to $852 million and 2027 guidance shows organic growth near 10% or more, and this passes; guidance for lower organic growth fails.
- Q3 2027 (estimate): First year of BioLife. Status: Pending. Watch: BioLife revenue grows and Repligen reports synergies of more than $20 million, and this passes; an impairment of BioLife assets fails.

## Balance sheet

- Cash: $863M
- Debt: $600M
- Net cash: $263M
- Last debt due: 2028

At September 30, 2026, Repligen had cash, cash equivalents and marketable securities of $863 million and 1.00% convertible notes due 2028 with a principal amount of $600 million. After that date, it paid about $564 million in cash for BioLife, issued $1,000 million of 0.25% convertible notes due 2031, of which $458.6 million was for cash, and retired $456.8 million of the 2028 notes. It planned to use $120.0 million of the cash to buy back shares. Debt principal after these steps is about $1,143.2 million.

As of 2026-09-30.

Sources:

- https://www.sec.gov/Archives/edgar/data/730272/000162828026068562/rgen-20260930.htm
- https://www.sec.gov/Archives/edgar/data/730272/000162828026071650/rgen-20261106.htm
- https://www.sec.gov/Archives/edgar/data/730272/000162828026068382/rgen-20261029.htm

## Dividends

Repligen does not pay a dividend.

Source: company filings and market data, read on 2026-11-12.

## Recent events

- 2026-11-06: Repligen issued $1,000 million of 0.25% convertible notes due 2031 with a conversion price of about $226.37. Of these, $541.4 million was in exchange for $456.8 million of its 2028 notes, and $458.6 million was for cash. $143.2 million of the 2028 notes remain.
- 2026-10-27: Repligen reported Q3 2026 results. Revenue grew 11% to $209.3 million, 12.5% organically. The GAAP loss per share was $0.68, after an impairment of $41.2 million, and adjusted EPS was $0.53. It raised 2026 revenue guidance to $844 million to $852 million.
- 2026-10-06: Repligen completed the purchase of BioLife Solutions. BioLife stockholders received $11.25 in cash and 0.1442 Repligen shares per share, about $564 million in cash and 7.2 million shares in total.
- 2026-07-21: Repligen agreed to buy BioLife Solutions. The company said that the deal adds to revenue growth and margins and that it expects more than $20 million of synergies in the first year.

## Latest news and filings

- Last earnings: 2026-10-27 (8-K: https://www.sec.gov/Archives/edgar/data/730272/000162828026067405/)
- Next earnings: 2027-02-23 (expected; the company has not confirmed it)

| Filed | Form | Headline | Period end | XBRL document | Link |
| --- | --- | --- | --- | --- | --- |
| 2026-11-06 | 8-K | New material agreement and New debt or financial obligation |  | rgen-20261106 | https://www.sec.gov/Archives/edgar/data/730272/000162828026071650/rgen-20261106.htm |
| 2026-10-30 | 10-Q | Quarterly report for the period ended Sep 30, 2026 | 2026-09-30 | rgen-20260930 | https://www.sec.gov/Archives/edgar/data/730272/000162828026068562/rgen-20260930.htm |
| 2026-10-30 | 8-K | Other company news |  | rgen-20261029 | https://www.sec.gov/Archives/edgar/data/730272/000162828026068382/rgen-20261029.htm |
| 2026-10-27 | 8-K | Earnings release |  | rgen-20261027 | https://www.sec.gov/Archives/edgar/data/730272/000162828026067405/ |
| 2026-10-06 | 8-K | Acquisition or sale completed and Investor disclosure |  |  | https://www.sec.gov/Archives/edgar/data/730272/000119312526415015/d240327d8k.htm |
| 2026-09-15 | 8-K | Change of directors or officers |  | rgen-20260910 | https://www.sec.gov/Archives/edgar/data/730272/000162828026062043/rgen-20260910.htm |
| 2026-09-08 | 8-K | Other company news |  |  | https://www.sec.gov/Archives/edgar/data/730272/000119312526385380/d131600d8k.htm |
| 2026-07-29 | 10-Q | Quarterly report for the period ended Jun 30, 2026 | 2026-06-30 | rgen-20260630 | https://www.sec.gov/Archives/edgar/data/730272/000119312526323773/rgen-20260630.htm |
| 2026-07-28 | 8-K | Earnings release |  | rgen-20260728 | https://www.sec.gov/Archives/edgar/data/730272/000119312526318853/ |
| 2026-07-22 | 8-K | New material agreement and Earnings release |  |  | https://www.sec.gov/Archives/edgar/data/730272/000119312526311402/ |

Every filing on SEC EDGAR (CIK 730272): https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000730272&type=&dateb=&owner=include&count=40

## Risks

- High: Demand depends on the spending of drug makers and biotech companies. Lower biotech funding or destocking by customers can cut orders.
- Medium: The integration of BioLife can take more time and cost than planned, and the cell therapy market is still small.
- Medium: Debt principal rose to about $1,143 million after the new convertible notes. The notes can add shares if the stock price rises above the conversion prices.
- Low: Repligen recorded a $41.2 million impairment of developed technology tied to a license agreement in Q3 2026.

## Links

- Page: https://picks.utilarium.app/company/RGEN/
- History of changes: https://picks.utilarium.app/company/RGEN/history/
- JSON with full history: https://picks.utilarium.app/data/company/RGEN.json

> Picks is a personal record of stock picks. It gives general opinions about stocks, including a "Top pick" label. They are not tailored to your needs, goals or risk tolerance. Kevin is not a registered adviser and relies on the general-advice exemption in Canadian securities law (NI 31-103 s.8.25). Do your own research, or ask a registered adviser. Kevin may hold any stock on this site. Prices, intrinsic values and ratings can be delayed or wrong; check the original source. Full disclaimer: /disclaimer/.
